Abstract
The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.
| Original language | English |
|---|---|
| Pages (from-to) | 1248 |
| Number of pages | 1 |
| Journal | Journal of Clinical Oncology |
| Volume | 38 |
| Issue number | 11 |
| DOIs |
|
| Publication status | Published - 2020 Apr 10 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 American Society of Clinical Oncology. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS